ArticleCancer medicine2025
RETRACTION: MiRNA-545 Negatively Regulates the Oncogenic Activity of EMS1 in Gastric Cancer.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Retraction of
Authors and funding
0 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
retractionM. Ma, J. Zhao, Q. Wu, K. Xiao, S. Li, H. Zhu, C. Liu, H. Xie, and C. Zuo, "MiRNA-545 Negatively Regulates the Oncogenic Activity of EMS1 in Gastric Cancer," Cancer Medicine 7, no. 6 (2018): 2452-2462, https://doi.org/10.1002/cam4.1520. The above article, published online on 07 May 2018 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors; the journal Editor-in-Chief, Stephen Tait; and John Wiley & Sons Ltd. The retraction has been agreed due to the use of contaminated cell lines in this article. Both the cell lines used to demonstrate the regulatory role of miR-545 in EMS1 expression (SGC-7901 & BGC-823) have been reported to be contaminated with HeLa [1, 2], as has cell line MGC-803 [3, 4]. Thus, the editors consider the conclusions of this article to be invalid. We did not find any evidence of misconduct by the authors. REFERENCES: [1] F. Ye, C. Chen, J. Qin, J. Liu, and C. Zheng, "Genetic Profiling Reveals an Alarming Rate of Cross-Contamination Among Human Cell Lines Used in China," The FASEB Journal 29, no. 10 (2015): 4268-4272, https://doi.org/10.1096/fj.14-266718. [2] X. Bian, Z. Yang, H. Feng, H. Sun, and Y. Liu, "A Combination of Species Identification and STR Profiling Identifies Cross-contaminated Cells from 482 Human Tumor Cell Lines," Scientific Reports 7 (2017): 9774, https://doi.org/10.1038/s41598-017-09660-w. [3] F. Cao, H. Sun, Z. Yang, Y. Bai, X. Hu, Y. Hou, X. Bian, and Y. Liu, "Multiple Approaches Revealed MGc80-3 as a Somatic Hybrid with HeLa Cells Rather than a Gastric Cancer Cell Line," International Journal of Cancer 154, no. 1 (2024): 155-168, https://doi.org/10.1002/ijc.34677. [4] M. Yang, J. He, S. Xia, Y. Wang, J. Xiong, C. Liao, N. Li, S. Qu, and C. Shen, "Investigation of the Mixed Origins of the MGC-803 Cell Line Reveals That It Is a Hybrid Cell Line Derived from HeLa," Human Cell 37 (2024): 560-566, https://doi.org/10.1007/s13577-023-01011-4.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.